Sofosbuvir + Ledipasvir

Paul G. Auwaerter, M.D., Janessa Smith M. Smith, PharmD, BCPS

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotypes 1, 4, 5 or 6 infections without cirrhosis or with compensated cirrhosis.
    • Also, genotype 1 with decompensated cirrhosis in combination with ribavirin.
    • Genotype 1 or 4 in liver transplant recipients without cirrhosis or with compensated cirrhosis with ribavirin.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 8, 2023